Clinical Trial

Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting

BOSTON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing…

10 months ago

VUZE Medical to Showcase Next Generation Software-based Guidance System for Spine Surgery at NASS 2023 Following FDA Filing

VUZE 2.0 designed to provide extended functionality, broader inter-operability while still requiring no tool modifications, cameras, markers or referencesRA’ANANA, Israel--(BUSINESS…

11 months ago

PaxMedica Announces Gold Sponsorship of The BRAIN Foundation’s Synchrony Symposia 2023

TARRYTOWN, NY / ACCESSWIRE / October 10, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a clinical stage biopharmaceutical company focusing on the…

11 months ago

Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy- -Company’s…

11 months ago

Carmot Therapeutics Announces that Preliminary Phase 1 Results Support Once-daily Oral Dosing for its Obesity and Type 2 Diabetes Candidate CT-996

BERKELEY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing…

11 months ago

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions

BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical…

11 months ago

American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea

-- Phase 3 Clinical Trials for AD109 Currently Enrolling Patients in the U.S.CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) --…

11 months ago

Cybrexa Therapeutics to Debut Preclinical Data Demonstrating CBX-15 is Safe and Highly Efficacious in 13762 Triple Negative Breast Cancer Model at 35th AACR-NCI-EORTC Symposium

Preclinical Data Demonstrate CBX-15's Anti-Tumor Efficacy in Animal Models and Ability to Enhance Immunogenicity and Induce Immune Memory through pH-Based…

11 months ago